Logo do repositório
 
Publicação

FDA boosts the Progressive Supranuclear Palsy Rating Scale!

dc.contributor.authorSampaio, Cristina
dc.date.accessioned2025-01-21T14:01:38Z
dc.date.available2025-01-21T14:01:38Z
dc.date.issued2024
dc.description© 2024 International Parkinson and Movement Disorder Society.pt_PT
dc.description.abstractGewily et al report on the significant modification of the well-established progressive supranuclear palsy rating scale (PSPRS), a process that was prompted and guided by feedback from the United States Food and Drug Administration (FDA). This study comprehensively compared the original (full PSPRS, 28 items) and the shortened only and shortened and rescored (PSPRS-10 and rPSPRS-10) versions of the PSPRS using item response theory (IRT). The study used data from 979 patients across four interventional clinical trials and two registries. The findings revealed that the PSPRS-10 contained 76% of the information from the full scale while demonstrating better unidimensionality and inter-item correlation. Some items in the full PSPRS showed poor correlation with disease severity, supporting the reduced scale to evaluate longitudinal disease progression. Power analyses indicated that PSPRS-10 was more effective than rPSPRS-10 in detecting treatment effects. The study concludes that focusing on the PSPRS-10 items is justified for assessing PSP severity and treatment effects in clinical trials, although rescoring may potentially weaken its sensitivity.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationMov Disord. 2024 Dec;39(12):2127-2129pt_PT
dc.identifier.doi10.1002/mds.30040pt_PT
dc.identifier.eissn1531-8257
dc.identifier.issn0885-3185
dc.identifier.urihttp://hdl.handle.net/10400.5/97414
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWileypt_PT
dc.relation.publisherversionhttps://movementdisorders.onlinelibrary.wiley.com/journal/15318257pt_PT
dc.titleFDA boosts the Progressive Supranuclear Palsy Rating Scale!pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage2129pt_PT
oaire.citation.issue12pt_PT
oaire.citation.startPage2127pt_PT
oaire.citation.titleMovement Disorderspt_PT
oaire.citation.volume39pt_PT
person.familyNameSampaio
person.givenNameCristina
person.identifier.orcid0000-0002-7052-9079
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationcb8e1445-bca9-4565-be74-e23dd4f191c1
relation.isAuthorOfPublication.latestForDiscoverycb8e1445-bca9-4565-be74-e23dd4f191c1

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
FDA_boosts.pdf
Tamanho:
97.68 KB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição: